In support of Pfizer’s five-point COVID-19 plan, Pfizer Global Supply colleagues in McPherson, Kansas, are manufacturing remdesivir for Gilead Sciences

Part of Pfizer’s five-point plan to address COVID-19 includes our commitment to using any excess manufacturing capacity and to potentially shifting production to support other companies’ efforts to expand the supply of investigational treatments for the disease.

That’s why Pfizer Global Supply colleagues in McPherson, Kansas, are manufacturing remdesivir for Gilead Sciences through Pfizer CentreOne, a global contract development and manufacturing organization embedded within Pfizer and a leading supplier of specialty active pharmaceutical ingredients.

“As the entire world continues to battle COVID-19, I am so proud of how our colleagues worked efficiently and collaboratively, demonstrating our Pfizer values of courage and excellence,” said Ian MacKellar, McPherson Site Leader. “This effort required both decisive decision-making and unrelenting attention to detail to help ensure safety, quality and compliance requirements were met under an accelerated timeframe. Our entire team has been honored to work with Gilead on this important endeavor to impact patients’ lives at such a critical time in our history.”

The McPherson team shipped the first clinical batch of remdesivir to Gilead ahead of the original target, as part of this new partnership that colleagues find “motivating and rewarding.”

“As Pfizer colleagues, we impact patients’ lives every day, but with this project, there was a heightened awareness of the need and ability to really make a difference,” said Lynn Goering, Senior Manager, Project Management.